Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

7.7%

8 terminated/withdrawn out of 104 trials

Success Rate

89.6%

+3.1% vs industry average

Late-Stage Pipeline

32%

33 trials in Phase 3/4

Results Transparency

16%

11 of 69 completed trials have results

Key Signals

8 recruiting11 with results6 terminated

Enrollment Performance

Analytics

Phase 2

32(42.7%)

Phase 3

18(24.0%)

Phase 4

15(20.0%)

Phase 1

7(9.3%)

N/A

3(4.0%)

75Total

Phase 2(32)

Phase 3(18)

Phase 4(15)

Phase 1(7)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (104)

Showing 20 of 104 trials

NCT07242248Recruiting

A Study to Observe Real-world Evidence of Guselkumab Treatment in Participants With Ulcerative Colitis and Crohn's Disease in the United Kingdom (UK)

Role: lead

NCT05347095Phase 3Active Not Recruiting

A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease

Role: lead

NCT05901649Active Not Recruiting

A Study for the Participants With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Treated With Androgen Deprivation Therapy (ADT) Plus Apalutamide or Enzalutamide

Role: lead

NCT06285318Recruiting

A Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With T-cell Redirectors Outside of Clinical Trials

Role: lead

NCT06472778Completed

A Real-world Study in Participants With Smoldering Multiple Myeloma

Role: lead

NCT06408935Phase 3Active Not Recruiting

Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients

Role: lead

NCT07449234Recruiting

A Study of Guselkumab After Switching From Ustekinumab in Participants With Moderate to Severe Psoriasis

Role: lead

NCT07532226Not Yet Recruiting

A Study of Guselkumab Treatment Persistence in Psoriatic Arthritis Participants

Role: lead

NCT06062537Active Not Recruiting

Analysis of Effectiveness and Safety of Teclistamab in Relapsed and Refractory Multiple Myeloma Patients

Role: collaborator

NCT01332955Phase 2Completed

Telaprevir in HIV-HCV Coinfected Patients Who Had Previously Failed a Peginterferon-Ribavirin Regimen

Role: collaborator

NCT03088124Phase 2Completed

Active Surveillance With or Without Apalutamide Treatment in Low Risk Prostate Cancer

Role: collaborator

NCT06038149Active Not Recruiting

Improving Pulmonary Hypertension Screening by Echocardiography

Role: collaborator

NCT03942497Completed

Clinical-pathological Characterization and Outcomes of Metastatic Urothelial Cancer in Latin America

Role: collaborator

NCT02125617Terminated

Urokinase Plasminogen Activator Receptor in Abiraterone Treated Patients With Castration Resistant Prostate Cancer

Role: collaborator

NCT06511648Phase 2Recruiting

Erdafitinib Monotherapy or in Combination With Cetrelimab in Muscle-invasive Bladder Cancer Patients With Fibroblast Growth Factor Receptor (FGFR ) Gene Alterations

Role: collaborator

NCT05590702Active Not Recruiting

French Observational Study of Patients With Chronic Lymphocytic Leukemia Or Small Lymphocytic Lymphoma in Real-World Settings

Role: collaborator

NCT02666898Phase 2Completed

Phase II Trial GA101 Inbrutinib B CLL

Role: collaborator

NCT04010968Phase 2Completed

Evaluation of Risk-Adapted and MRD-Driven Strategy for Untreated Fit Patients With Intermediate Risk Chronic Lymphocytic Leukemia

Role: collaborator

NCT04829318Phase 4Completed

A Long-Term Extension Study for Participants With Treatment-resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray Treatment

Role: lead

NCT07110662Phase 1Not Yet Recruiting

New Therapeutic Target for Toxic Epidermal Necrolysis (TEN) Using Anti-CD38+ Monoclonal Antibodies.

Role: collaborator